Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase

15 Mar 2017

Abstract excerpt

// Corinna Kosnopfel 1 , Tobias Sinnberg 1 , Birgit Sauer 1 , Heike Niessner 1 , Anja Schmitt 2 , Elena Makino 1 , Andrea Forschner 1 , Stephan Hailfinger 2 , Claus Garbe 1 , Birgit Schittek 1 1 Division of Dermatooncology, Department of Dermatology, University of Tübingen, Tübingen, Germany 2 Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany Correspondence to: Birgit Schittek,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Melanoma and MAPK Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28415756
DOI: 10.18632/oncotarget.16204

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinasePMID 28415756Read ↗

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasionSemantic proximity Read ↗

Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.Semantic proximity Read ↗

Analysis of BRAF inhibitor resistance in melanoma cellsSemantic proximity Read ↗

The c-Jun/RHOB/AKT pathway confers resistance ofBRAF-mutant melanoma cells to MAPK inhibitorsSemantic proximity Read ↗

BRAF inhibitors: resistance and the promise of combination treatments for melanomaSemantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1Semantic proximity Read ↗

BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current KnowledgeSemantic proximity Read ↗

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSemantic proximity Read ↗

Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.